Swamy Vijayan

A drug-discovery factory that fits on a benchtop

Walk into most screening labs and you will hear robots. Arms swinging, tips dropping, plates clacking from station to station. Swamy Vijayan looked at that orchestra and decided the instrument was wrong. At Zafrens, the San Diego company he cofounded in 2021 with Yi Zhang, scale doesn't come from more machines. It comes from a chip.

The chip is called Z-Screen. Where a standard lab plate holds 96 wells, a single Zafrens chip carries between 50,000 and 200,000 microwells - and every one of them can image a living cell and read its RNA at the same time. The reach that used to be priced for big pharma now runs daily, at single-cell resolution, on a benchtop. Millions of experiments a day, no robot army required.

What you get out the other end isn't a single number. It's a map. Zafrens links a genetic or chemical nudge to the molecular response it triggers to the way the cell actually behaves afterward. Perturbation, genotype, phenotype - the three things drug hunters usually measure in separate experiments, stitched into one.

That phrase - anywhere in the world - is the tell. Vijayan isn't selling a faster centrifuge. He is trying to decentralize a capability that has lived behind the walls of a handful of pharmaceutical campuses, and hand it to anyone with a lab and a question.

A physicist who got bored, and got useful

Here is the origin story he refuses to dress up. Vijayan's move into the life sciences, by his own account, was built on dissatisfaction with theoretical physics - not a childhood love of cells. He had a PhD in physics from the University of Pennsylvania and a polymer-science background, and he went looking for a field where that toolkit could do something.

He found it at the seams. Optics, molecular biology, nanofabrication, computation - the boring middle ground between disciplines where most people don't want to live. Vijayan moved in. He started at BioNanomatrix as an integration scientist, then ran the Nanobiology group at Illumina, leading research on new ways to read DNA.

The habit that made it work is almost comically simple. When he enters a new field, he buys the beginner textbook. He rebuilds intuition from the first chapter, on purpose, because he believes the value hides in being able to think across the walls instead of staying expert inside one room.

Three companies, one move repeated

Vijayan has run three companies as founder or CEO, and they rhyme. Each takes a tool that was expensive, fiddly and gatekept, and makes it cheap, simple and parallel.

First came Omniome, founded to simplify DNA sequencing instrumentation. It pushed advances across plasmonic sensing, optical detection, nucleotide chemistry and polymerase engineering, and in 2021 Pacific Biosciences acquired it for up to $800 million.

Then Plexium, where the same instinct showed up in a different costume: a 150,000-well plate format built to replace the humble 96-well plate for screening DNA-encoded libraries, in service of turning protein binders into protein degraders.

And now Zafrens, where the well count climbs again and imaging plus sequencing get folded into every well. Read the resume sideways and it stops looking like three jobs. It looks like one long argument: the bottleneck in biology is throughput at resolution, and you fix it by shrinking the experiment, not buying more robots.

From molecular state to what the cell actually does

The cleverness of Zafrens isn't only the count of wells. It's what each well captures. Vijayan describes the payoff in a single line that, once you sit with it, is enormous:

Translation: it isn't enough to know which genes flicker on. You want to know what the cell then goes and does - whether a CAR-T cell kills, whether a co-culture behaves, whether a compound works through the mechanism you hoped. Zafrens runs longitudinal co-culture experiments across many cell types and ties the molecular readout to the functional outcome. Its tools carry names that say the quiet part out loud: active-seq and active-drug-seq.

And the data exhaust is becoming its own asset. Vijayan has been blunt about where this heads, pointing at the predictive models trained on Zafrens' uncommonly rich datasets.

The money that believed the chip

When Zafrens stepped out of stealth, it did so with $23 million in financing led by Prime Movers Lab, the fund built around hard-science companies most generalist investors flinch at. The syndicate around it reads like a list of people comfortable with biology that looks like engineering: BlueYard Capital, KOFA Healthcare, Global Brains, FoundersX Ventures, Alix Ventures, Possible Ventures, Iaso Ventures and Hawktail.

The pitch they bought wasn't a single drug or a single target. It was infrastructure - a platform that could run multiple stages of drug discovery inside one experiment, at a scale that used to require a pharmaceutical balance sheet. In early 2025 the company added a Series A extension to keep scaling the Z-Screen platform and the data engine growing on top of it.

It is the kind of bet that only makes sense if you believe the bottleneck Vijayan keeps naming - throughput at resolution - is real, and that whoever solves it owns a layer everyone else has to build on.

Shared purpose beats a roomful of opinions

For a man who prizes thinking across disciplines, Vijayan has a counterintuitive view of who you put in a founding room. In the earliest days, he argues, what matters most is not a parade of diverse viewpoints but a shared purpose and vision - a small group rowing in the same direction before the boat is even built.

It tracks with the rest of his philosophy. If your aim is a company meant to last a century, the first hires aren't there to debate the destination. They're there because they already see it. The breadth - the optics person, the molecular biologist, the computation lead, the nanofabrication mind - matters enormously, but only once everyone agrees on why the thing exists. Purpose first, perspectives second.

Building for 2120, not for the exit

Most founders talk about the next round. Vijayan talks in centuries, and means it as an engineering spec rather than a flourish.

It is a strange thing to hear from someone whose last company was acquired for nine figures. The exit, in his telling, was never the point - the platform was. He optimizes for the durable thing: a base that outlives any single product, any single drug, any single founder. In a field that prizes the fast flip, building something meant to be inherited is its own kind of contrarian.